ANL vs BBNX: fair value comparison
Adlai Nortye Group Ltd. and Beta Bionics, Inc. · Updated 2026-10-19
ANL has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. BBNX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, ANL currently ranks higher by quality score.
| ANL | BBNX | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $11.03 | $16.35 |
| 12-month range | $0.88–$16.60 | $8.86–$31.99 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #94 of 301 Healthcare | #96 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | — | Expanding |
| Revenue growth | High | High |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: ANL fair value analysis · BBNX fair value analysis